New hope for leukemia patients: asciminib shows promise in indian study
NCT ID NCT06427811
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at the safety and effectiveness of a drug called asciminib in 85 Indian adults with a specific type of leukemia (Ph+ CML-CP). Some participants had a genetic mutation (T315I) that can make treatment harder, while others had already tried two or more other drugs. The goal was to confirm that asciminib works and is safe for these patients, as part of a post-approval requirement by Indian health authorities.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis Investigative Site
Ahmedabad, Gujarat, 380009, India
-
Novartis Investigative Site
Ahmedabad, Gujarat, 382428, India
-
Novartis Investigative Site
Bengaluru, Karnataka, 560034, India
-
Novartis Investigative Site
Trivandrum, Kerala, 695 011, India
-
Novartis Investigative Site
Pune, Maharashtra, 422001, India
-
Novartis Investigative Site
New Delhi, National Capital Territory of Delhi, 431005, India
-
Novartis Investigative Site
Hyderabad, Telangana, 500082, India
-
Novartis Investigative Site
Kolkata, West Bengal, 700014, India
-
Novartis Investigative Site
Cuttack, 753007, India
-
Novartis Investigative Site
Guwahati, 781003, India
More trials for these conditions
Other studies related to the condition(s) this trial covers.